Cloverleaf Therapeutics - 19104 Philadelphia, PA

Business Name: Cloverleaf Therapeutics
Categorized In: Research and Development Laboratories
Address: 3160 Chestnut St # 200, Philadelphia, PA 19104
Phone Number: (314) 524-4291
Contact Person: Xiaolu Yang
NAICS Code: 541712
SIC Code: 8731
Business Type: B2B (Business to Business)
Employee #: 1 to 4
Location Type: Single Location
Annual Revenue ($): $50.000 to $99.999
Share This Business:
Similar Businesses: Fibradigm Therapeutics LLC - Philadelphia, PA 19104
Cellulosic Biotherapeutics LLC - Philadelphia, PA 19104
Axonia Medical LLC - Philadelphia, PA 19104
Micropathid D Iagnostics LLC - Philadelphia, PA 19104
Myostratum LLC - Philadelphia, PA 19104
Neuronai LLC - Philadelphia, PA 19104
Invidisyn LLC - Philadelphia, PA 19104
Oxygense - Philadelphia, PA 19104
Relgene LLC - Philadelphia, PA 19104
Translatum LLC - Philadelphia, PA 19104
Biosucran - Philadelphia, PA 19104
Sante Biosciences - Philadelphia, PA 19104
Cognizance Biomarkers LLC - Philadelphia, PA 19104
Wilson Robert D MD - Philadelphia, PA 19104
Graphene Frontiers LLC - Philadelphia, PA 19104
Anosos Biotherapeutics LLC - Philadelphia, PA 19104
Sunstone Biosciences Inc - Philadelphia, PA 19104
Quern Therapeutics - Philadelphia, PA 19104
Innofect - Philadelphia, PA 19104
Mitergy LLC - Philadelphia, PA 19104

Cloverleaf Therapeutics provides professional Research and Development Laboratories from its single location at the coordinates 39.953553,-75.18659.

The company offers B2B variables under the SIC code 8731 and NAICS code 541712, while making an annual revenue of $50.000 to $99.999 and hiring a total of 1 to 4 employees.

Founded in 0, the company can now be visited at 3160 Chestnut St # 200, Philadelphia, Pennsylvania 19104 or contacted through representative Xiaolu Yang at (314) 524-4291.

For frequently asked questions and further inquiries about professional Research and Development Laboratories, get to know more about Cloverleaf Therapeutics through its company website at . Engage with this business on its social media platforms through on Twitter and on Facebook.